April 11, 2025 – In the latest episode of Oncopeptalks, David and Sofia discuss the recent market turbulence, status of the company and Stockholm as a life science region, among other things.
April 1, 2025 – Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.
March 13, 2025
In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.
Read moreFebruary 4, 2025
On Friday, January 31, the Danish Medicines Council, an independent council that produces recommendations and guidelines on medicines for the country's five regions, published a decision to recommend a restriction on the use of the drug lenalidomide.
Read moreApril 1, 2025
Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.
Read moreFebruary 25, 2025
Oncopeptides AB today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology.
Read moreNovember 20, 2024
Oncopeptides today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10.
Read more
March 21, 2025
CEO Sofia Heigis recently presented the company at the Redeye event followed by a Q&A.
Read more
March 12, 2025
Oncopeptides’ CEO Sofia Heigis recently presented the company at the Aktiespararna event Stora Aktiedagarna in Stockholm, Sweden. The presentation was followed by a Q&A with the moderator from Aktiespararna.
Read morePress release - April 1, 2025
2025-04-15 - 2025-05-14
Other
2025-04-28
Report
2025-05-15
Report
Released February 27, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.
